Fmr LLC Compass Therapeutics, Inc. Transaction History

Fmr LLC

$1.49 Trillion
Q1 2025

A detailed history of Fmr LLC transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 4,134,287 shares of CMPX stock, worth $8.81 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,134,287

Previous 4,136,403 0.05%

Holding current value

$8.81 Million

Previous $6 Million 30.98%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$1.4 - $3.9 $2,962 - $8,252	-2,116 Reduced 0.05%	4,134,287 $7.86 Million
Q4 2024 Feb 13, 2025	BUY	$1.35 - $1.98 $175 - $257	130 Added 0.0%	4,136,403 $6 Million
Q3 2024 Nov 13, 2024	BUY	$0.8 - $1.88 $4,718 - $11,088	5,898 Added 0.14%	4,136,273 $7.61 Million
Q2 2024 Aug 13, 2024	SELL	$1.0 - $1.85 $384,762 - $711,809	-384,762 Reduced 8.52%	4,130,375 $4.13 Million
Q1 2024 May 13, 2024	SELL	$1.2 - $2.29 $43,642 - $83,285	-36,369 Reduced 0.8%	4,515,137 $8.94 Million
Q4 2023 Feb 13, 2024	SELL	$1.4 - $1.98 $2,221 - $3,142	-1,587 Reduced 0.03%	4,551,506 $7.1 Million
Q3 2023 Nov 13, 2023	SELL	$1.87 - $3.25 $1.84 Million - $3.19 Million	-982,413 Reduced 17.75%	4,553,093 $8.97 Million
Q2 2023 Aug 11, 2023	SELL	$2.64 - $3.48 $384,294 - $506,569	-145,566 Reduced 2.56%	5,535,506 $17.6 Million
Q1 2023 May 11, 2023	SELL	$3.14 - $5.48 $2.12 Million - $3.69 Million	-673,742 Reduced 10.6%	5,681,072 $18.6 Million
Q3 2022 Nov 10, 2022	SELL	$1.9 - $3.37 $983,440 - $1.74 Million	-517,600 Reduced 7.53%	6,354,814 $14.5 Million
Q4 2021 Feb 14, 2022	BUY	$2.88 - $3.98 $19.8 Million - $27.4 Million	6,872,414 New	6,872,414 $21.8 Million

Others Institutions Holding CMPX

# of Institutions

127

Shares Held

101M

Call Options Held

2.52M

Put Options Held

3.1M

View Full List

About Compass Therapeutics, Inc.

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $216M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

More about CMPX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account